Journal of Clinical Oncology
Articles in this Issue
Long-term efficacy and patient experience with neoadjuvant cabozantinib for locally advanced renal cell carcinoma.
511 Background: Our phase 2 trial (NCT04022343) established that neoadjuvant cabozantinib provided clinical benefit in hig...
Interim safety analysis of a randomized phase II trial comparing pembrolizumab with radiation versus pembrolizumab, olaparib, and radiation in localized high risk prostate cancer.
362 Background: Preclinical data suggest synergy between immune checkpoint blockade, PARP inhibition, and radiation. This...
Early prediction of PSA nadir in metastatic castration-sensitive prostate cancer with machine learning approaches.
222 Background: Early achievement of PSA nadir is a well-established prognostic marker in mHSPC. Understanding PSA kinetic...
Investigation of the natural killer (NK) cell axis in decoy-resistant IL18 treatment in bladder cancer (BCa).
790 Background: Bladder cancer (BCa) is the most common malignancy of the urinary tract and the sixth most prevalent cance...
A multicenter phase II study of first-line modified FOLFIRINOX in patients with advanced urachal cancer (ULTIMA; KCSG GU20-03).
758 Background: There is no established standard treatment for recurrent or metastatic urachal cancer (UrC). Combination r...
Predictive value of microsatellite instability/mismatch repair deficiency phenotype in upper tract urothelial carcinoma: A systematic review and meta-analysis.
701 Background: Lynch syndrome (LS) has been established as a significant risk factor for developing upper tract urothelia...
Real-world analysis of renal cell carcinoma with sarcomatoid differentiation treated with first-line immunotherapy combinations: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
448 Background: Sarcomatoid renal cell carcinoma (sRCC) is aggressive with poor outcomes. Dual checkpoint blockade (nivolu...
Genomic heterogeneity in urothelial carcinoma with trophoblastic differentiation: Real world data.
858 Background: Urothelial carcinoma with trophoblastic differentiation (TUC) represents a rare and aggressive variant tha...
Promoter methylation of aquaporin 1 as a prognostic biomarker in clear cell renal cell carcinoma.
518 Background: Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer, yet reliable biomarkers...
Immune senescence and antigen presentation defects in BCG-unresponsive bladder cancer.
823 Background: Intravesical Bacillus Calmette-Guérin (BCG) remains the cornerstone therapy for high-risk non–muscle invas...
Clinical and demographic disparities in prostate cancer patients undergoing radical prostatectomy: A 20-year retrospective cohort study from the United States.
205 Background: Radical prostatectomy remains a cornerstone treatment for localized prostate cancer. Understanding factors...
Perioperative outcomes of open versus robot-assisted radical nephrectomy with IVC thrombectomy.
468 Background: Renal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus presents complex surgical challeng...
Cost-effectiveness analysis of new perioperative treatment regimens for muscle-invasive bladder cancer in Germany.
648 Background: The NIAGARA trial investigated the efficacy of adding perioperative durvalumab to standard gemcitabine/cis...
A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY): Interim analysis.
187 Background: Advanced metastatic castration-resistant prostate cancer (mCRPC) remains a largely lethal disease with lim...
Patient-reported outcomes (PRO) from a dose-escalation and expansion trial of fractionated and multiple-cycle PSMA-targeted alpha radionuclide <sup>225</sup> Ac-J591.
208 Background: A prior phase I dose-escalation study demonstrated encouraging safety and efficacy of single administratio...
Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated between 2021-2025.
94 Background: The Rx landscape for mCRPC has shifted significantly in recent years with the introduction of poly(ADP-ribo...
Twenty-five years of bladder cancer mortality in the U.S. (1999–2024).
658 Background: Bladder cancer is the sixth most common malignancy in the United States and remains a significant contribu...
Features of early and late recurrence versus de novo metastatic ccRCC: Findings from JAVELIN Renal 101.
544 Background: Many patients with clear cell renal cell carcinoma (ccRCC) recur after nephrectomy, yet how these recurren...
A novel method of analysis that uses standard of care PSA values to help guide optimal treatment decisions in the management of metastatic prostate cancer.
61 Background: Metastatic prostate cancer is commonly treated with androgen deprivation therapy (ADT) combined with abirat...
Influence of body composition on the efficacy of chemotherapy in men with metastatic aggressive variant prostate cancer (AVPC).
200 Background: Higher levels of adiposity have been associated with an improved response to AR pathway inhibition (ARPI)...
Effect of digital Ki67-based risk modeling on prognostic precision in non–muscle-invasive bladder cancer and high-risk subsets in mixed-grade tumors.
642 Background: Grade is a major determinant of progression in non–muscle-invasive bladder cancer (NMIBC), but tumor heter...
Optimal hour of immune checkpoint inhibitors (ICIs) administration in metastatic renal cell carcinoma (mRCC): The “Tic-Tac” study.
452 Background: Recent studies suggest that early time-of-day (ToD) ICI-administration improves outcomes in metastatic can...
Early prostate specific antigen response and overall survival in metastatic hormone sensitive prostate cancer: Real-world data on age, body mass index, and treatment.
109 Background: Prostate-specific antigen (PSA) response is a strong prognostic marker for overall survival (OS) in metast...
Phase 2 study of ASP5541 (PRL-02), a long-acting intramuscular depot injection of abiraterone decanoate, in patients with advanced prostate cancer.
TPS300 Background: Globally, prostate cancer (PC) is the second most diagnosed cancer in men and fifth leading cause of ca...
Hormone therapy use and duration with post-operative radiotherapy for recurrent prostate cancer: An individual patient data meta-analysis.
305 Background: Addition of hormonal therapy (HT) to definitive radiotherapy (RT) in localized prostate cancer improves ov...